Ferumoxytol for the treatment of iron deficiency anemia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, originally approved for iron deficiency in chronic kidney disease, received a broad label for any cause of iron deficiency after oral iron intolerance or in those circumstances when oral iron is ineffective or harmful. Areas covered: The chemistry, pharmacology and pharmacokinetics of ferumoxytol were reviewed. Retrospective, observational, and prospective phase II and III trials were reviewed. When appropriate, comparative safety and efficacy parameters were reported. Differentiation between minor infusion reactions and more severe hypersensitivity reactions that may lead to anaphylaxis is described. Expert commentary: Ferumoxytol is a safe and effective iron formulation providing a means of iron repletion in persons with iron deficiency with or without anemia. Relative to iron sucrose, ferric gluconate, and iron dextran and similar to ferric carboxymaltose and iron isomaltoside, ferumoxytol yields relatively low quantities of labile free iron. Hypersensitivity and anaphylaxis is extremely rare. Hypophosphatemia with ferumoxytol's administration is extremely rare. Optimal strategies for application of ferumoxytol-enhanced imaging and full replacement dosing in a single setting remain to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jahn, M. R., Andreasen, H. B., Fütterer, S., Nawroth, T., Schünemann, V., Kolb, U., Hofmeister, W., Muñoz, M., Bock, K., Meldal, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.03.016 · Cited by 256 · cited 2×
“approximately 60% of that observed with iron dextran, still a sizeable quantity [3].”
BackgroundHoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P., & Overstreet, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0150-2 · Cited by 211 · cited 1×
“While the amount of labile free iron in ferumoxytol is significantly lower than iron sucrose, ferric gluconate and iron dextran and similar to ferric carboxymaltose and iron isomaltoside, it is more than negligible and the extremely rapid administration (30 mg/1 mL per second) likely resulted in the large number of re…”
Result
Cited by
Potential Toxicity of Iron Oxide Magnetic Nanoparticles: A Review
Malhotra, N., Lee, J.-S., Liman, R. A. D., Ruallo, J. M. S., Villaflores, O. B., Ger, T.-R., & Hsiao, C.-D. (2020) · Molecules · doi:10.3390/molecules25143159 · Cited by 470
Kim, H. Y., Kim, T. J., Kang, L., Kim, Y.-J., Kang, M. K., Kim, J., Ryu, J. H., Hyeon, T., Yoon, B.-W., Ko, S.-B., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119942 · Cited by 321
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels
Trujillo-Alonso, V., Pratt, E. C., Zong, H., Lara-Martinez, A., Kaittanis, C., Rabie, M. O., Longo, V., Becker, M. W., Roboz, G. J., Grimm, J., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0406-1 · Cited by 319
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Wu, D., Chang, X., Tian, J., Kang, L., Wu, Y., Liu, J., Wu, X., Huang, Y., Gao, B., Wang, H., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00958-6 · Cited by 263
Metadata
- Authors
- Auerbach, M., Chertow, G. M., & Rosner, M.
- Venue
- Expert Review of Hematology
- Publisher
- Informa UK Limited
- Published
- 2018-09-14
- Volume
- 11
- Issue
- 10
- Pages
- 829-834
- ISSN
- 1747-4086 (ISSN-L)
- 1747-4094
- OpenAlex
- W2891853812
- Cited by
- 54
- References
- 2
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ferumoxytol for the treatment of iron deficiency anemia. https://app.cochat.ai/papers/10.1080/17474086.2018.1518712
- The paper
- Auerbach, M., Chertow, G. M., & Rosner, M. (2018). Ferumoxytol for the treatment of iron deficiency anemia. Expert Review of Hematology. https://doi.org/10.1080/17474086.2018.1518712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.